Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy

NCCN guidelines for first-line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) patients without targetable driver alterations includes either immunotherapy alone or in combination with chemotherapy. In this study, we investigated genomic predictors of survival after immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebot, Ericka M., Duncan, Daniel L., Tolba, Khaled, Fabrizio, David, Frampton, Garrett M., Comment, Leah A., Albacker, Lee A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225995/
https://www.ncbi.nlm.nih.gov/pubmed/35739333
http://dx.doi.org/10.1038/s41698-022-00286-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225995/
https://www.ncbi.nlm.nih.gov/pubmed/35739333
http://dx.doi.org/10.1038/s41698-022-00286-4

Ejemplares similares